Experts support continued use of Aranesp in certain kidney patients

10/18/2010 | Bloomberg

An FDA advisory panel voted 15-1 for continued use of Amgen's Aranesp in nondialysis patients with chronic kidney disease. The panel also voted 9-5 against lowering dosing for patients with blood hemoglobin levels less than 9 grams per deciliter. The advisers recommended further studies to determine the ideal dosing and to identify which patients benefit from Aranesp.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA